WilmerHale Advises PTC Therapeutics on Public Offering

WilmerHale Advises PTC Therapeutics on Public Offering

Client News

Related Solutions

Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On January 23, 2019, PTC Therapeutics, Inc. (NASDAQ: PTCT), a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders, announced the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of $30.20, before underwriting discounts. In addition, PTC has granted the underwriter an option for a period of 30 days to purchase up to an additional 1,008,000 shares of common stock at the public offering price, less the underwriting discount. The closing of the offering took place on January 25, 2019.

WilmerHale represented PTC, with Brian Johnson leading the legal advisory team.

Read more about the firm's involvement.


Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel